Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
AstraZeneca plans to initiate a 2-part open-label, randomized, crossover, multicenter, non-therapeutic phase II study to investigate the presence of exocrine pancreatic insufficiency (EPI) in patients with type 2 diabetes mellitus, and to investigate the pharmacokinetics of Epanova (omega-3 carboxylic acids) and Omacor (omega-3-acid ethyl esters) following a single oral dose in patients with different degrees of EPI.
The official title of the study is “A Two-part, Open-label, Randomised, Crossover, Multicentre, Phase II Study to Investigate the Presence of Pancreatic Exocrine Insufficiency (PEI) in Patients With Type 2 Diabetes Mellitus, and to Investigate the Pharmacokinetics of EPANOVA® and OMACOR® Following a Single Oral Dose in Patients With Different Degrees of PEI.”
http://www.hcplive.com/news/Europea...ncy-in-Patients-with-Type-2-Diabetes-Mellitus
The official title of the study is “A Two-part, Open-label, Randomised, Crossover, Multicentre, Phase II Study to Investigate the Presence of Pancreatic Exocrine Insufficiency (PEI) in Patients With Type 2 Diabetes Mellitus, and to Investigate the Pharmacokinetics of EPANOVA® and OMACOR® Following a Single Oral Dose in Patients With Different Degrees of PEI.”
http://www.hcplive.com/news/Europea...ncy-in-Patients-with-Type-2-Diabetes-Mellitus